158 related articles for article (PubMed ID: 19097775)
1. Recommendations for the assessment of progression in randomised cancer treatment trials.
Dancey JE; Dodd LE; Ford R; Kaplan R; Mooney M; Rubinstein L; Schwartz LH; Shankar L; Therasse P
Eur J Cancer; 2009 Jan; 45(2):281-9. PubMed ID: 19097775
[TBL] [Abstract][Full Text] [Related]
2. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
3. Analysis of progression-free survival in oncology trials: some common statistical issues.
Carroll KJ
Pharm Stat; 2007; 6(2):99-113. PubMed ID: 17243095
[TBL] [Abstract][Full Text] [Related]
4. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU
Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737
[TBL] [Abstract][Full Text] [Related]
5. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
Zhang JJ; Zhang L; Chen H; Murgo AJ; Dodd LE; Pazdur R; Sridhara R
Clin Cancer Res; 2013 May; 19(10):2637-45. PubMed ID: 23532893
[TBL] [Abstract][Full Text] [Related]
6. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
7. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
Pignatti F; Hemmings R; Jonsson B
Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
[No Abstract] [Full Text] [Related]
8. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
Robinson AG; Booth CM; Eisenhauer EA
Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
[TBL] [Abstract][Full Text] [Related]
9. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
10. General and statistical hierarchy of appropriate biologic endpoints.
Sargent D
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
[TBL] [Abstract][Full Text] [Related]
11. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
12. Proposal for the use of progression-free survival in unblinded randomized trials.
Freidlin B; Korn EL; Hunsberger S; Gray R; Saxman S; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2122-6. PubMed ID: 17513819
[TBL] [Abstract][Full Text] [Related]
13. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
14. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
Dodd LE; Korn EL; Freidlin B; Jaffe CC; Rubinstein LV; Dancey J; Mooney MM
J Clin Oncol; 2008 Aug; 26(22):3791-6. PubMed ID: 18669467
[TBL] [Abstract][Full Text] [Related]
15. Effects of cancer drugs on survival: often poorly evaluated.
Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
17. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
18. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.
Morita S; Sakamaki K; Yin G
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25956357
[TBL] [Abstract][Full Text] [Related]
19. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
[TBL] [Abstract][Full Text] [Related]
20. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Zhuang SH; Xiu L; Elsayed YA
Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
